JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Inclusion Criteria: * Participants must be able to provide an archived tumor sample * Histologically or cytologically confirmed solid tumors with KRAS G12C mutation * Must have received at least 1 prior standard therapy * Must have at least 1 measurable lesion per RECIST v1.1 * Must have adequate organ function * Must be able to swallow and retain orally administered medication Exclusion Criteria: * Has brain or spinal metastases, except if treated and no evidence of radiographic progression or hemorrhage for at least 28 days * Active infection requiring systemic treatment within 7 days * Active HBV or HCV * Any severe and/or uncontrolled medical conditions * LVEF ≤50% assessed by ECHO or QTcF * QT interval \>470 msec * Experiencing unresolved CTCAE 5.0 Grade \>1 toxicities